

Date: 6th August, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of extract of Unaudited Financial Results for the quarter ended 30th June, 2025, published in 'Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 6th August, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Company Secretary

Encl.: A/a.



ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123

Regd.Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2025

(₹ in Crores except per share data)

CARLO AND THE CONTRACTOR OF TH	(< iii Grores except per snare data)		
A Property of the Control of the Con	Quarter Ended		Year Ended
Particulars	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
Total Income from Operations	1,710.72	1,561.73	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	190.10	157.03	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	190.10	157.03	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	154.38	134.71	583.42
Total Comprehensive Income for the period	154.33	131.21	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year			5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.85	6.84	29.68

Notes:

		Quarte	Quarter Ended	
1.	Standalone details	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
	Income from Operations	1,494.17	1,475.56	6,032.63
	Profit Before Tax	125.52	213.20	595.72
	Profit After Tax	103.52	176.19	503.12

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



Place: Vadodara

Date: 5th August, 2025

For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin Chairman and CEO

WWW.INDIANEXPRESS.COM THE INDIAN EXPRESS, WEDNESDAY, AUGUST 6, 2025



Regd.Office: Alembic Road, Vadodara - 390 003 Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2025

	(4 III Ololes except her silate data)			
AND DESCRIPTION OF THE PROPERTY OF THE PROPERT	Quarter Ended		Year Ended	
Particulars	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)	
Total Income from Operations	1,710.72	1,561.73	6,672.08	
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	190.10	157.03	694.31	
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	190.10	157.03	707.18	
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	154.38	134.71	583.42	
Total Comprehensive Income for the period	154.33	131.21	587.54	
Equity Share Capital	39.31	39.31	39.31	
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year		<u>-</u>	5,151.63	
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.85	6.84	29.68	

Notes:

1.		Quarte	Quarter Ended	
	Standalone details	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
	Income from Operations	1,494.17	1,475.56	6,032.63
	Profit Before Tax	125.52	213.20	595.72
	Profit After Tax	103.52	176.19	503.12

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



Place: Vadodara Date : 5th August, 2025 For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin Chairman and CEO

Alembic Touching Lives over

ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123 Regd.Office: Alembic Road, Vadodara - 390 003 Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Unaudited Financial Results for the guarter ended 30th June, 2025

ı	for the quarter ended of June, 2020				
in the same of the		(₹ in Cr	(₹ in Crores except per share data)		
not be the agreement of their in land	Quarter Ended Year End		Year Ended		
	Particulars	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)	
l	Total Income from Operations	1,710.72	1,561.73	6,672.08	
	Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	190.10	157.03	694.31	
	Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	190.10	157.03	707.18	
The second district of the second	Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	154.38	134.71	583.42	
	Total Comprehensive Income for the period	154.33	131.21	587.54	
	Equity Share Capital	39.31	39.31	39.31	
The same of the sa	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year			5,151.63	
Total Control of the last of t	Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.85	6.84	29.68	

Notes:

1.	Standalone details	Quarter	Quarter Ended	
		30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
	Income from Operations	1,494.17	1,475.56	6,032.63
	Profit Before Tax	125.52	213.20	595.72
	Profit After Tax	103.52	176.19	503.12

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



Place : Vadodara

Date : 5th August, 2025

For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin Chairman and CEO